Clinical trials: Specific Immunotherapy
Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults
Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
The aim of this clinical study is to evaluate the feasibility and safety of an individualized peptide vaccination approach in patients with acute lymphoblastic leukemia (ALL).
- Trial name
- NCT03559413
- Testing
- Individual peptide vaccination with adjuvant GM-CSF and Imiquimod
- Where
- 5 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University Children's Hospital Tuebingen
Type 1 Diabetes
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
The study is a two centre, open-label, uncontrolled single group phase 1A study of C19-A3 GNP peptide (10 μg peptide equivalent content) administered via Nanopass microneedles every 28 days for 8 weeks (3 doses), with follow-up…
- Trial name
- EE-ASI-1 (NCT02837094)
- Testing
- C19-A3 GNP
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Cardiff University
Cancer
Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells
The primary objectives are to evaluate the safety and efficacy of infusion of autologous tumor associated antigen-specific engineered immune effector cells (EIE).
- Trial name
- NCT03535246
- Testing
- Engineered Immune Cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Peanut Allergy
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
The objectives of this open-label follow-up study for subjects who previously were randomized and have completed the VIPES study for the treatment of peanut allergy, are: To assess the efficacy of Viaskin Peanut after up to 36…
- Trial name
- OLFUS-VIPES (NCT01955109)
- Testing
- Viaskin Peanut 250 mcg
- Where
- 22 sites in United States, Canada and 2 more
- Volunteers
- 171 people
- Sponsor
- DBV Technologies
Allergic Rhinoconjunctivitis
Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children
Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering…
- Trial name
- NCT00841256
- Testing
- Grass pollen allergens in a water/glycerol solution
- Where
- Germany
- Volunteers
- 207 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Asthma
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
The purpose of this study is to determine whether a short course of subcutaneous immunotherapy is efficacious in mite induced asthma. The efficacy is based on reduction in control medication.
- Trial name
- NCT00492076
- Testing
- Pangramin Plus D. pteronyssinus 100%
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis
Safety of Lymph Node Injection for Allergen Immunotherapy
The purpose of this study is to determine safety of allergy immunotherapy lymph node injections for grass pollen allergies.
- Trial name
- NCT01982474
- Testing
- Grass pollen extract
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Amber Patterson
Relapsed Neuroblastoma, Refractory Neuroblastoma
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma
- Trial name
- NCT03635632
- Testing
- C7R-GD2.CART cells
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- Baylor College of Medicine
Food Hypersensitivity, Immune System Diseases
Oral Immunotherapy in Food Allergy in Finland
The outcomes of oral immunotherapy (OIT) in food allergy study will provide more knowledge of oral immunotherapy. So far the OIT has showed in clinical experiments to be a interesting way to increase the unresponsiveness in…
- Conditions
- Food Hypersensitivity, Immune System Diseases, Anaphylaxis
- Trial name
- NCT02640014
- Testing
- Milk
- Where
- Finland
- Volunteers
- 250 people
- Sponsor
- Helsinki University Central Hospital
Lymphoma, Follicular, Lymphoma, Small Lymphocytic
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Primary Objectives: To document the efficacy of treatment with autologous lymphoma-derived HSPPC-96 of selected patients with indolent lymphoma.
- Trial name
- NCT00081809
- Testing
- autologous human tumor-derived HSPPC-96
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Agenus Inc.
B Cell Leukemia
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
Patients with relapsed leukemia often develop resistance to chemotherapy. For this reason, we are attempting to use a patient's own T cells, which can be genetically modified to expresses a chimeric antigen receptor(CAR).
- Trial name
- NCT01683279
- Testing
- Autologous CD19 CAR+ EGFTt + T cells
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Seattle Children's Hospital
Neuroblastoma, Ganglioneuroblastoma
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
Patients with recurrent or refractory neuroblastoma are resistance to conventional chemotherapy. For this reason, the investigators are attempting to use T cells obtained directly from the patient, which can be genetically…
- Trial name
- NCT02311621
- Testing
- Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Seattle Children's Hospital
Respiratory Hypersensitivity
Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma
The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.
- Trial name
- NCT00263640
- Testing
- Acaroid
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Allergopharma GmbH & Co. KG
Infection, Precancerous/Nonmalignant Condition
Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection
RATIONALE: Collecting the T cells from a donor and transplanting them into a patient may be effective treatment for immunodeficiency syndrome and CMV infection.
- Trial name
- NCT00547235
- Testing
- therapeutic allogeneic lymphocytes, allogeneic bone marrow transplantation, total-body irradiation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Melanoma
Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells
This protocol was conducted as a single institution trial at Hoag Cancer Center, Hoag Hospital, Newport Beach, California. It was a single-arm phase II trial in which patients with metastatic melanoma received subcutaneous (s.c.)…
- Trial name
- DCVaccineMel (NCT00948480)
- Testing
- Autologous tumor cells plus dendritic cells, GM-CSF
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Cancer
Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis
The primary objective of this study is to verify the safety of antigen-specific T cells (CAR-T) and engineered immune effector cytotoxic T cells (EIE) modified by immunoregulatory genes and immune modified dendritic cell vaccine…
- Trial name
- NCT04085159
- Testing
- Antigen-specific T cells CART/CTL and DCvac
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
This study investigates whether the specific carbohydrate diet (SCD) can maintain clinical remission in pediatric and adult patients with Crohn's disease.
- Trial name
- SCD (NCT01749813)
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Stanford University
Grass Pollen Allergy, Specific Immunotherapy
Regulatory T-cells After Subcutaneous Immunotherapy
The primary endpoint was the induction of T-regulatory cells under s specific subcutaneous immunotherapy (SCIT). Patients suffering from grass pollen allergy (relevant clinical symptomes during the pollen season, Skin Prick test…
- Trial name
- RTCAS (NCT01830673)
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Hymenoptera Sting Allergy
Frequency of Hymenoptera-stings in Patients Under Allergen-Specific Immunotherapy (SIT)
In Switzerland, 3.5% of the population are suffering from hymenoptera venom allergy. The only causal treatment of hymenoptera alelrty is venom specific immunotherapy.
- Trial name
- ZU-HVA-001 (NCT00742794)
- Testing
- Observation
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University of Zurich
Lymphoma
Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory to stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00182650
- Testing
- aldesleukin, rituximab, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- City of Hope Medical Center